Rozlytrek (entrectinib)

pCPA File Number: 22065
Negotiation Status:
Under consideration for negotiation
Indication(s):
treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, and with no satisfactory treatment options
Sponsor/Manufacturer:
HOFFMANN-LA ROCHE LIMITED
CADTH Project Number:
PC0278
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable